The Science of PureNADH

No miracle claim. Just a molecule, a formulation challenge, and the evidence that matters.

NADH has a defined role in cellular energy metabolism. That does not automatically prove what an oral supplement will do. Follow the evidence from the real molecular structure to electron transfer, formulation, and product verification.

Follow the evidence See the formulation
The molecule shown is NADH (C₂₁H₂₉N₇O₁₄P₂).

Verified NADH molecular structure · PubChem CID 439153 · Drag to rotate

01 — The molecule

What NADH actually is

NADH is the reduced form of NAD⁺, or nicotinamide adenine dinucleotide, a coenzyme used in redox reactions throughout living cells.

Its nicotinamide ring carries a hydride equivalent: two electrons and one proton. That electron-carrying state is what distinguishes NADH from NAD⁺.

NAD⁺ · oxidized form NADH · reduced form 2e⁻ + H⁺ C₂₁H₂₉N₇O₁₄P₂
NADH is not ATP. It carries reducing equivalents used upstream of ATP synthesis.

This is established cell biology. It is not, by itself, evidence of what supplemental NADH does after ingestion.

See the handoff →

02 — The mechanism

The handoff, not the hype

In the mitochondrial matrix, NADH transfers a pair of electrons to Complex I and is oxidized back to NAD⁺.

Those electrons continue through the respiratory chain. The free energy released during that transfer supports proton pumping across the inner mitochondrial membrane.

When protons flow back through ATP synthase, the enzyme uses that electrochemical gradient to form ATP from ADP and phosphate.

Simplified physiology of mitochondrial NADH oxidation. This animation does not depict the journey or effect of supplemental NADH.

Inside a mitochondrion, NADH makes a handoff. It donates two electrons to Complex I and returns to its oxidized form, NAD⁺. Those electrons then move through the respiratory chain. Complexes I, III, and IV use that flow to pump protons across the inner membrane, building an electrochemical gradient. When the protons return through ATP synthase, the enzyme uses that force to form ATP from ADP and phosphate. NADH does not become ATP. It helps start the chain that makes ATP formation possible.
  1. NADH donates two electrons to Complex I NADH → NAD⁺ + 2e⁻
  2. Electrons move through the respiratory chain
  3. Complexes I, III and IV pump H⁺ outward
  4. The H⁺ gradient stores potential
  5. ATP synthase uses the gradient to form ATP ADP + Pi → ATP
1 of 5 · Electron donation
NADH electron transfer and ATP formation Five-step schematic. NADH donates electrons to Complex I. Electrons move through the respiratory chain. Complexes pump protons across the inner mitochondrial membrane. The gradient drives ATP synthase, which forms ATP from ADP and phosphate. INTERMEMBRANE SPACE MITOCHONDRIAL MATRIX IComplex I IIIComplex III IVComplex IV ATPATP synthase NADHNADH → NAD⁺ + 2e⁻ electron flowO₂ → H₂O H⁺ returnsADP + Pi NADH donates two electrons to Complex I.

Step 1: NADH donates two electrons to Complex I.

Interactive schematic · NADH oxidation inside a mitochondrion. Not a depiction of the supplemental product.

NADH does not turn into ATP. It contributes electrons to the process that makes ATP.
03 — What the mechanism proves

Cell biology tells us where to look. It does not settle the supplement question.

Biochemistry establishes what NADH does inside cells. It does not establish that swallowed NADH remains intact, reaches circulation, enters cells, changes mitochondrial NADH, or improves how a person feels.

Those are separate questions requiring separate evidence.

Established

Established cell biology

  • NADH structure and redox role
  • Electron transfer into Complex I
  • Proton-gradient coupling to ATP synthase

Requires product testing

Requires finished-product testing

  • Chemical identity and NADH amount per capsule
  • Potency through the stated shelf life
  • Release under defined gastric and intestinal conditions

Requires human evidence

Requires product-relevant human evidence

  • Systemic exposure or bioavailability
  • Cellular or mitochondrial delivery
  • Biological or felt outcomes

We keep these evidence levels separate throughout this page.

See why formulation matters →

04 — Condition-sensitive chemistry

Before NADH can matter, it has to still be NADH.

The reduced form can oxidize to NAD⁺ and undergo other changes under unfavorable conditions. In laboratory systems, NADH stability is influenced by factors including pH, temperature, buffer composition, and UV exposure.

This does not mean every molecule is destroyed instantly. It means formulation, packaging, storage, and analytical verification matter.

Identity→ Shelf stability→ Release→ Exposure→ Human outcome
"Stabilized" should describe a measured result, not a marketing adjective.

Published stability research describes NADH under specific laboratory conditions. It is not a test of the finished PureNADH product.

See the PureNADH design →

05 — Formulation design

Three formulation choices. Three distinct jobs.

PureNADH combines a freeze-dried NADH ingredient, a cyclodextrin-based formulation, and an acid-resistant capsule.

These choices are intended to address different formulation checkpoints. Design explains the intent; finished-product testing must establish performance.

Formulation concept · not to scale · design intent, not performance proof

01Dry

Freeze-dried NADH

Lyophilization removes water during processing to create a dry NADH format.

Design intentLimit water present during manufacturing and support dry-state handling.
Evidence requiredResidual moisture, NADH assay, degradation profile, and finished-product stability.
02Formulate

Cyclodextrin-based matrix

PureNADH uses a cyclodextrin-based formulation as a component of the finished product.

Design intentA formulation component intended to support the NADH ingredient. Exact identity and purpose are documented in the formulation dossier.
Evidence requiredExact identity and ratio, finished-form complexation if claimed, comparative stability, and release behavior.
03Release

Acid-resistant capsule

The capsule is designed to delay opening under acidic conditions and release its contents later in the digestive process.

Evidence requiredFinished-product dissolution or release testing under defined gastric and intestinal conditions.
Formulation explains intent. Testing establishes performance.
Patent pending

A U.S. patent application is pending covering aspects of our formulation.

Patent-pending status describes a filed application. It does not establish product efficacy, safety, stability, or absorption.

Review the product evidence →

06 — Product evidence

Trust should be downloadable.

A badge or adjective is not enough. Each product claim should point to a method, sample, result, date, and responsible laboratory.

Only reports testing the finished PureNADH product should be presented as PureNADH-specific proof.

Identity and assay

Does the finished capsule contain the stated form and amount of NADH?

In progress

Stability

How much NADH remains through the stated shelf life and storage conditions?

In progress

Dissolution or release

How does the finished capsule release under defined gastric and intestinal conditions?

In progress

Contaminants and microbiology

What was tested, on which lot, by which laboratory, and against which specification?

Not yet established

Manufacturing credentials

Which facility, standard, certifier, scope, and validity period apply?

Not yet established
Every published result will carry: Batch · Test date · Laboratory · Method · Specification · Result · Limitation.

Patent status does not establish clinical efficacy. Facility certification does not establish human outcomes.

07 — From product to person

The label amount is the beginning of the evidence chain, not the end.

The Supplement Facts panel lists 100 mg of NADH per capsule. That number does not by itself establish retained shelf-life potency, release, absorption, an optimal dose, or a greater effect.

Published oral NADH studies vary in dose, formulation, population, duration, and outcome. Research on another formulation cannot be treated as a trial of PureNADH.

Ingredient identity→ Dose integrity→ Release→ Absorption→ Systemic exposure→ Target tissue→ Biological endpoint→ Human outcome

Every checkpoint needs its own evidence. This is a sequence of questions, not a completeness status.

Every cited study must state whether it investigated:

  • Established NADH biology
  • Another oral NADH formulation
  • The finished PureNADH product

If PureNADH has not been studied for an outcome, this page says so.

Mechanism ≠ bioavailability Ingredient study ≠ product study Testimonial ≠ controlled outcome

International Expertise

Meet our Scientific Advisory Board

Interdisciplinary expertise with international recognition in nutrition and pharmacy is a core part of the PureNADH team. It enables us to develop products like PureNADH to the highest quality standards, setting new benchmarks.

Midhat Jasic, PhD

Professor Emeritus, Nutrition & Food Science

Emilija Aleksovska, M.Pharm.

Pharmaceutical
Formulation Lead

Jana Hartmann, PhD

Neuroscientist
& Cell Biologist

Quality is in our DNA

Pharmaceutical-Grade Quality You Can Verify

Made in an FDA-registered, GMP-certified facility.
Every batch is independently third-party tested for purity and potency

Dietary supplements often have an image problem for good reason: nutrient density, stability, or bioavailability are frequently unreliable. The reason: usually costs for quality assurance and profit orientation.

PureNADH stands for uncompromising quality: highest purity, stability, and bioavailability, at fair prices. For noticeable effects!

Certified Quality and Purity

Each batch is tested in certified laboratories for heavy metals, contaminants, and microorganisms. Our GMP-certified production facility meets ISO 22000 and HACCP standards, certified by TÜV Thüringen and DakkS.

PDF
Test Report
PDF
View Report
PureNADH 100 mg NADH capsules, product bottle

10 — The evidence at a glance

Make the decision from what is shown, not what is implied.

Established

NADH is the reduced form of NAD⁺. It transfers electrons into cellular respiration, while ATP is produced downstream using an electrochemical proton gradient.

Formulated

PureNADH is labeled to contain 100 mg of NADH and uses freeze-drying, a cyclodextrin-based formulation, and an acid-resistant capsule.

Product-dependent

Retained shelf-life potency, dissolution behavior, systemic exposure, and human outcomes each require their own relevant evidence.

Review the complete Supplement Facts, other ingredients, directions, warnings, price, and return terms before deciding.

View PureNADH product details Return to the evidence

100 mg labeled NADH per capsule · Full ingredients and directions on the product page

PureNADH is a dietary supplement, not a treatment. No outcome is guaranteed. Follow the label. If you are pregnant, nursing, managing a medical condition, taking medication, or are unsure whether the product is appropriate for you, consult a qualified healthcare professional before use.

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Sources you can inspect

Mechanism references explain endogenous NADH biology. They are not evidence of PureNADH absorption or product outcomes.